Smoldering MM - Myeloma Expert Guidance - Interactive Virtual Presentation - Myeloma Therapeutic Strategies - Oncology

Smoldering Multiple Myeloma (19 minutes)

Expert discussion of risk stratification for patients with smoldering myeloma and new data on initial management options for patients with high-risk smoldering multiple myeloma.

Peter M. Voorhees, MD

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Released: June 23, 2020 Expiration: June 22, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:

Plan management of patients based on an accurate diagnosis of monoclonal gammopathy of undetermined significance, smoldering MM, or active MM

Create individualized treatment strategies for patients with newly diagnosed MM through consideration of the available clinical data as well as risk assessment, age, comorbidities, and patient preferences

Evaluate the efficacy and safety evidence of combination regimens to individualize therapeutic strategies for patients with MM at first relapse

Plan appropriate treatment strategies using all available agents and classes to provide efficacious combination therapies to heavily pretreated patients with relapsed/refractory MM

Employ novel agents and clinical trial participation as part of clinical care strategies for MM

Information on this Educational Activity

Faculty

Peter M. Voorhees, MD

Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute
Charlotte, North Carolina

Peter M. Voorhees, MD, has no relevant conflicts of interest to report.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has reported that his spouse/partner has ownership interest (stock) in AstraZeneca.

Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to report.

June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Target Audience

This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with MM and also patients with MM.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with myeloma.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 23, 2020, through June 22, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

CAR T-Cell Therapy: Applying the Data, Tailoring Treatment, and Future Considerations

View Multimedia

Free video from Clinical Care Options featuring expert discussion of the latest updates in CAR T-cell therapy for hematologic cancers

Michael R. Bishop, MD
Program Director

Daniel J. DeAngelo, MD, PhD

Noopur Raje, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ ABIM MOC: maximum of 1.5 Medical Knowledge MOC point(s) Released: August 14, 2020 Expired: August 13, 2021

Introduction and Overview of CAR T-Cell Therapy (14 mins)

CAR T-Cell Therapy Against NHL and CLL: Current and Emerging Clinical Trial Evidence (34 mins)

Review of Clinical Outcomes of CAR T-Cell Therapies for ALL (19 mins)

CAR T-Cell Therapy for Myeloma (17 mins)

Identifying and Managing CAR T-Cell–Mediated Toxicities (8 mins)

ClinicalThought